KPV
Also known as: Lys-Pro-Val
Molecular Identifiers
Overview
Anti-inflammatory tripeptide derived from α-MSH (amino acids 11-13). Research in gut health. Can be administered orally or subcutaneously.
KPV Lys-Pro-Val Half-life
~30-60 minutes
Administration Route
Subcutaneous, oral, or topical
Category
Specialized Research
Mechanism of Action
- Inhibition of the NF-κB pathway
- Potent anti-inflammatory effect
- Modulation of pro-inflammatory cytokines
- Intestinal barrier protection
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 500-1000 mcg per injection |
| Frequency | 1-2 times daily |
| Timing | Any time of day |
| Duration | 4-8 weeks |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Pain at injection site (rare)
- Mild skin irritation (topical)
Product Properties
| Purity | >98% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Highly stable as a tripeptide. Protect from light and moisture. Avoid repeated freeze-thaw cycles. |
Presentations & Preparation
Vials of KPV found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on KPV.
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D
Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease
Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W, Kucharzik T
Related Peptides
Aviptadil
50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol
B7-33
100-500 mcg per injection (subcutaneous) · Once daily
Bronchogen
5-10 mg per day via subcutaneous injection · Once daily
Cardiogen
5-10 mg per day subcutaneously · Once daily
Chonluten
5-10 mg per day subcutaneously · Once daily
Crystagen
5-10 mg per day via subcutaneous injection · Once daily